Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Individuals must meet all inclusion criteria listed below in order to be eligible to participate in the study.~* Males and females between the ages of 18 and 80 with mild to moderate active psoriasis.~* Female subjects of child-bearing ability willing to commit to reliable contraception while participating in the study.~* Ability to provide informed consent~* Willingness and ability to participate in required study procedures~EXCLUSION CRITERIA:~* Severe psoriasis by PASI (Psoriasis Area and Severity Index) score \> 12~* Currently being treated with biologic immune modifying agents.~* Currently on treatment for allergies or other inflammatory diseases.~* Currently taking a multivitamin, Vitamin B or tryptophan supplementation and unwilling to stop within 2 weeks of baseline visit.~* Unwillingness/inability to provide informed consent~* ALT \> x3 upper limit of normal, hepatic insufficiency or active liver disease~* Recent history of acute gout~* Chronic renal insufficiency with creatinine \> 2.5mg/dl~* Pregnant (or attempting to become pregnant) women~* Current participation in another drug study~* History of intolerance to NR precursor compounds, including niacin or nicotinamide~* Study adherence concerns~* Individuals with diabetes type 1 and 2 who use insulin~* Women of child-bearing potential unwilling to use contraception or unwilling to practice abstinence~* Breastfeeding women unwilling to stop breastfeeding~* Immunization administered within 30 days of participation and no plans for immunization while participating in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Participants with mild to moderate Psoriasis receiving Placebo (Type: PLACEBO_COMPARATOR): Participants with mild to moderate Psoriasis receiving placebo (2 capsules) twice daily by mouth for 28 days.
- Participants with mild to moderate Psoriasis receiving Nicotinamide Riboside (Type: EXPERIMENTAL): Participants with mild to moderate Psoriasis receiving Nicotinamide Riboside Chloride 500mg (2 capsules) twice daily by mouth for 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).